diffuse large B-cell lymphoma with secondary CNS involvement
Conditions
Interventions
Observation group:None
Sponsors
The First Affiliated Hospital of Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with diffuse large B-cell lymphoma confirmed by histopathology; 2. Age 18-80 years old; 3. Previously received rituximab; 4. CNS involvement at presentation (concomitant to systemic disease); 5. At least 1 measurable disease site; 6. The cardiopulmonary function is basically normal; 7. The observed patients have signed the informed consent to participate in the experimental treatment; 8. The observed patient has signed the informed consent to participate in this observational treatment; 9. Volunteer to participate in this study, sign the informed consent before screening and be willing to follow and able to complete all test procedures.
Exclusion criteria
Exclusion criteria: 1. Previous medical history of other malignant tumors; 2. Women of childbearing age with recent birth plans; 3. Uncontrollable active infection; 4. Human immunodeficiency virus (HIV) / AIDS; 5. Difficult to control or serious cardiovascular disease; 6. Possible allergy, allergy, or intolerance to the study drug; 7. Serious diseases that may interfere with the study; 8. Patients received another research drug at the same time; 9. According to the judgment of the researcher, the patient has other conditions that are not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival;Duration of Response;Overall Survival;Adverse events;Prognostic biomarkers; | — |
Countries
China
Contacts
Public ContactZhiyong Zeng
Outcome results
None listed